DaVita Inc. (DVA) $145.58
DaVita finds itself at a critical juncture, having dipped below its lower Bollinger Band today, yet the broader technical picture suggests underlying strength.
52-wk High $159.42
📌 Investment Snapshot
- 💰 Trading at $145.58 with a 15.3x TTM P/E, a discount to the S&P 500 average.
- 📈 Q4 2025 saw revenue hit $3.62B and EPS surge to $3.29, marking strong sequential growth.
- 🔑 Significant institutional backing, notably from Berkshire Hathaway, underpins long-term confidence.
- 🎯 Analysts project a mean target of $151.71, implying a modest 4.2% upside from current levels.
DaVita currently trades below its lower Bollinger Band, signaling short-term oversold conditions, yet its RSI remains above the traditional oversold threshold. While the stock has enjoyed a robust 28% rally over the past three months, recent momentum indicators like the MACD suggest a bearish cross.
| 📍 Entry Zone | $141.50 or below | 🛑 Stop-Loss | $139.00 |
| 📋 Adjust If | DVA reclaims $148.00 with sustained volume, signaling a reversal of the short-term downtrend. | ||
The Investment Case — Why Now?
DaVita’s recent operational performance paints a compelling picture, with Q4 2025 revenue reaching $3.62 billion and EPS jumping to $3.29. This strong financial footing, coupled with active share buybacks and a significant stake from Berkshire Hathaway, underscores a robust underlying business. However, the stock has recently pulled back, dropping 5.5% over the last month and 3.44% today.
The immediate challenge for DVA lies in its current technical positioning. The stock now tests a critical confluence of support levels, including its 50-day Simple Moving Average at $143.04 and a bullish Fair Value Gap between $141.56 and $144.34. A decisive break below these levels could trigger further downside, despite the company’s fundamental strength.
🤔 Does DaVita’s recent operational strength justify buying into this technical dip, or does the limited analyst upside signal caution?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | DaVita Inc. |
| Ticker / Exchange | DVA / NYSE |
| Sector / Industry | Healthcare / Medical Care Facilities |
| CEO | Javier J. Rodriguez |
| Founded / HQ | 1994 / Denver, CO |
📈 Price Action & Technicals
Dead Cross
Inside VA
A buy-side sweep occurred at $147.21 on March 13, which the price has now broken below.
DaVita’s current price of $145.58 sits below its lower Bollinger Band, signaling a short-term oversold condition. Despite today’s dip, the stock maintains a bullish posture above both its 50-day SMA at $143.04 and its 200-day SMA at $131.96, indicating a healthy underlying trend.
Momentum indicators present a mixed picture: the RSI at 40.8 suggests neutral territory, not yet signaling an oversold bounce. The MACD, however, shows a bearish crossover, with the MACD line falling below its signal line. The ADX at 13.2 confirms no strong trend is currently in play, but the -DI exceeding the +DI indicates prevailing bearish momentum.
From a structural perspective, DVA remains well-supported. The price trades above its Anchored VWAP from January 14 at $138.11 and comfortably within the Volume Profile’s Value Area ($115.02-$154.75), also sitting above the Point of Control at $130.21. These elements contribute to the Strong Technical Confluence Score of 80/100, suggesting long-term accumulation.
Today’s volume is running 22% above its 20-day average, accompanying the price decline. This confirms the selling pressure. Notably, the price has dipped below a recent buy-side liquidity sweep at $147.21, suggesting that prior institutional demand at that level has been overcome by sellers.
The confluence of a short-term oversold signal (Bollinger Band breach) against a backdrop of long-term structural strength (SMAs, VWAP, Volume Profile) creates a critical decision point. Historically, such divergences often precede either a sharp rebound from key support or a deeper search for liquidity.
🤔 Given the conflicting short-term bearish signals against a strong long-term technical backdrop, what specific price level would confirm a sustained rebound for DVA?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| DVA | DaVita Inc. | 15.3x |
| HCA | HCA Healthcare | 17.0x |
| UHS | Universal Health Services | 13.5x |
| SEM | Select Medical Holdings | 14.0x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $3.62B | $3.29 | |
| Q3 2025 | $3.42B | $2.04 | |
| Q2 2025 | $3.38B | $2.58 | |
| Q1 2025 | $3.22B | $2.00 |
DaVita generated a robust $0.4 billion in Free Cash Flow in the latest quarter, demonstrating strong operational efficiency. The company actively returned capital to shareholders through $0.3 billion in share buybacks, signaling management’s confidence and commitment to shareholder value.
🚀 Growth Drivers — What Moves the Stock
- Aging Population & Chronic Kidney Disease 🟡 Priced In — The increasing prevalence of chronic kidney disease (CKD) among an aging global population ensures a steady, growing demand for dialysis services. This demographic tailwind provides a stable foundation for DaVita’s core business.
- Shift to Value-Based Care 🟢 Upside Surprise — DaVita’s strategic focus on value-based care models, which emphasize patient outcomes and cost efficiency, positions the company for improved profitability and market share. Successful execution could unlock significant upside by reducing healthcare costs and enhancing patient quality of life.
- Geographic Expansion & Strategic M&A 🟢 Upside Surprise — Opportunities for expanding its footprint in underserved domestic markets and select international regions, coupled with strategic acquisitions, could drive inorganic growth. This allows DaVita to broaden its patient reach and service offerings.
🤔 With DVA’s core business tied to an aging demographic, how much additional growth can truly be unlocked through new value-based care models?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Berkshire Hathaway, Inc | 31,759 |
| Vanguard Group Inc | 4,154 |
| Blackrock Inc. | 2,926 |
| Invesco Ltd. | 1,683 |
| Morgan Stanley | 1,477 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| RODRIGUEZ JAVIER J | Chief Executive Officer | Mar 13, 2026 | Award | 20,900 |
| BERRY CHRISTOPHER MICHAEL | Officer | Mar 13, 2026 | Award | 3,649 |
| WATERS KATHLEEN ALYCE | Officer | Mar 13, 2026 | Award | 3,185 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.2% | 6.6 |
⚠ Key Risk Factors
~$500M+ impact
~$100-200M impact
~$50M+ impact
~$50-100M impact
🤔 How resilient is DaVita’s business model to potential cuts in government reimbursement rates, a perennial risk for healthcare providers?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $190.0 | $151.71 | $126.0 | 7 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| UBS | Buy | Feb 2026 | Maintains | |
| Barclays | Equal-Weight | Feb 2026 | Maintains | |
| TD Cowen | Hold | Nov 2025 | Maintains | |
| B of A Securities | Underperform | Sep 2025 | Maintains |
Analyst sentiment for DaVita remains largely cautious, with a consensus ‘Hold’ rating and a mean price target offering only 4.2% upside. This suggests that while the company’s fundamentals are acknowledged, significant near-term catalysts for outperformance are not widely anticipated.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong Q4 2025 earnings and robust Free Cash Flow demonstrate operational excellence and financial health.
- Significant institutional backing, particularly from Berkshire Hathaway, signals high-conviction long-term investment.
- Demographic tailwinds from an aging population ensure sustained demand for dialysis services, providing a stable revenue base.
📊 Base Case
Our base case assumes DaVita continues to execute on its value-based care initiatives, maintains stable patient volumes, and effectively navigates regulatory pressures. This scenario projects steady, albeit moderate, growth in line with analyst expectations.
🐻 Bear Case
- Adverse changes in government reimbursement policies or unexpected increases in labor costs could severely impact profitability.
- A failure to hold key technical support levels, such as the 50-day SMA and bullish FVG, could trigger a deeper correction.
- Intensified competition or a slower-than-expected adoption of value-based care models might constrain revenue and margin expansion.
🎯 Investor Action Plan — By Profile
Stay on the sidelines for now. Look for a confirmed bounce from the $141.50-$144.34 bullish FVG zone or a decisive reclaim of $148.00 on strong volume, targeting a quick move to $152.00 with a stop below $139.00.
Hold existing positions if your long-term thesis remains intact. For new capital, consider scaling into a position if DVA tests the $141.50-$144.00 range, establishing a stop-loss below $139.00 to protect against further downside.
Maintain your long-term conviction in DaVita’s stable business model and demographic tailwinds. Use any deeper pullbacks towards the $130.00-$135.00 range (near the VP POC and larger FVG) as potential opportunities to add to your position, if your risk tolerance allows.
❓ Investor FAQ — People Also Ask
Q: What’s driving DaVita’s recent stock performance?
DaVita has experienced a strong 28.1% rally over the past three months, fueled by robust Q4 2025 earnings and active share buybacks. However, the stock has recently pulled back 5.5% over the last month, with today’s 3.44% drop pushing it below its lower Bollinger Band, signaling short-term weakness.
Q: How does DaVita’s valuation compare to its peers?
Trading at 15.3x TTM P/E, DaVita appears undervalued compared to the S&P 500 average of 21.0x. While it trades at a slight premium to some peers like Universal Health Services (13.5x) and Select Medical Holdings (14.0x), it remains below HCA Healthcare (17.0x), suggesting a reasonable valuation within its sector.
Q: What are the key technical levels to watch for DVA?
Investors should closely monitor the $141.56-$144.34 bullish Fair Value Gap and the 50-day SMA at $143.04 as immediate support. A break below these could lead to a test of the Anchored VWAP at $138.11. On the upside, reclaiming $148.00 would signal a potential reversal, with the bearish FVG at $151.19-$152.08 acting as resistance.
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is provided for informational purposes only and does not constitute investment advice. All investment decisions should be made based on your own research and financial situation. Past performance is not indicative of future results. Consult with a qualified financial advisor before making any investment decisions.
All active positions and their real-time performance are tracked on our Investment Log.
#DVA #DaVitaInc #HealthcareStocks #StockAnalysis #TechnicalAnalysis #ValueInvesting #USStocks #Veqtio